It’s time.
Dedicated to advancing novel treatments for patients living with severe, genetic disorders associated with the liver.
It’s time.
Dedicated to advancing novel treatments for patients living with severe, genetic disorders associated with the liver.
It’s time.
Dedicated to advancing novel treatments for patients living with severe, genetic disorders associated with the liver.

Portfolio of gene therapy treatment

Dimension’s programs address significant unmet medical needs for patients living with hemophilia and rare diseases associated with the liver. The Company’s lead program in OTC deficiency is currently in phase I/II clinical testing. The company is also advancing programs through preclinical testing to address glycogen storage disease type Ia (GSDIa), phenylketonuria (PKU), Wilson disease, citrullinemia type 1, and hemophilia A, the latter in collaboration with Bayer.

Dimension’s therapies use the biology of the parvovirus (adeno-associated virus (AAV)) to carry the missing gene in the body to the target cell with the aim of correcting the defect and providing meaningful clinical benefit to the lives of patients. This platform has demonstrated early validation and compelling preclinical in vivo proof of concept across multiple disease states in leading academic research centers. / Learn More /

GENE THERAPY

Dimension’s approach selectively targets the replacement of missing intact genes to treat diverse rare diseases.

AAV Platform
Selectively targeting liver cells to deliver missing intact genes
Pipeline
Addressing severe, rare genetic disorders
About Us
Thought leaders with expertise in orphan products

Featured Program

Glycogen Storage Disease Type Ia (GSDIa)

GSD Type Ia (GSDIa) is the most common, genetically inherited glycogen storage disease. Individuals with GSDIa have a defective gene for the enzyme glucose-6-phosphatase, resulting in the inability to regulate blood sugar (glucose).

NEWS
August 8, 2017
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
July 24, 2017
Dimension Therapeutics Announces Management Change
June 27, 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
May 10, 2017
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update